AVECHO BIOTECHNOLOGY LIMITED — Director's Dealing 2015

Jul 9, 2015

==> picture [232 x 40] intentionally omitted <==

ASX Limited Market Announcements Office

Final Director’s Interest Notice – Mr H Rosen

10 July 2015, Melbourne: Phosphagenics Limited (ASX: POH; OTCQX: PPGNY)

Further to the Company’s announcement of 8 July 2015 advising that Mr H Rosen has stepped down as an executive and as a Director of Phosphagenics Limited.

Attached for release to the market is the Appendix 3Z - Final Director’s Interest Notice.

ENDS

Enquiries

David Segal Investor Relations Manager Phosphagenics Limited +61 3 9565 1103

About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM[® ] (Targeted Penetration Matrix). TPM[®] is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. Phosphagenics’ lead product advancing through clinical trials is an oxycodone patch for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forwardlooking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168 PO Box 1415, Clayton South MDC VIC 3169 Australia Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151 www.phosphagenics.com Email: info@phosphagenics.com

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity PHOSPHAGENICS LIMITED ABN 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director Harry ROSEN

Date of last notice 13 March 2008 (Appendix 3Y)

Date that director ceased to be director 8 July 2015

Part 1 – Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities - Nil

• See chapter 19 for defined terms.

Appendix 3Z Page 1

11/3/2002

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interestNote: Provide details of the circumstances giving rise tothe relevant interestParoha Nominees Pty Ltd (i)Paroha Nominees Pty Ltd (ii)(Superannuation A/c)Total Interest	Number & class of securitiesORDS 61,367,143ORDS 2,859,293________________64,226,436________________(i)Mr Rosen is a director of Paroha Nominees Pty Ltdand holds an interest in excess of 20 per cent inParoha Nominees Pty Ltd(ii)Mr Rosen may be a beneficiary under theSuperannuation Plan of which Paroha NomineesPty Ltd is a Trustee

Part 3 – Director’s interests in contracts

Detail of contract	None
Nature of interest
Name of registered holder(if issued securities)
No. and class of securities to whichinterest relates

p\asx\3z hr 08 07 15

• See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002